Literature DB >> 30234599

Increased influenza-specific antibody avidity in HIV-infected women compared with HIV-infected men on antiretroviral therapy.

Zhenwu Luo1, Elizabeth Ogunrinde1, Min Li1, Lumin Zhang2, Lisa Martin3, Zejun Zhou1, Zhiliang Hu1,4, Tao Zhang1,5, Zhen Li1,6, Jiafeng Zhang1,7, Bin Su6, Tong Zhang6, Hao Wu6, Lei Ma8, Guoyang Liao8, Allison Ross Eckard3,9, Maria Anna Julia Westerink1,3, Sonya L Heath10, Wei Jiang1,3.   

Abstract

BACKGROUND: It is recommended that HIV-infected individuals receive annual influenza vaccination due to their high susceptibility to influenza infection, especially among women. However, there have been few studies investigating sex-related responses to influenza vaccine in antiretroviral therapy (ART)-treated HIV-infected individuals.
METHOD: In this study, 26 aviremic ART-treated HIV-infected individuals and 16 healthy controls were enrolled in the current study. Blood was collected prior to vaccination (D0), on days 7-10 (D7) and on days 14-21 (D14) following administration of the 2013-2014 seasonal influenza vaccine. A series of analyses evaluated the serological and cellular responses following influenza vaccination.
RESULTS: Female HIV-infected individuals had increased influenza-specific antibody avidity relative to male HIV-infected individuals, but similar plasma levels of influenza-specific binding antibodies and neutralizing antibodies. Increased cycling B cells and follicular helper CD4 T (Tfh) cells were observed in female HIV-infected individuals pre and postvaccination compared with male HIV-infected individuals, and cycling Tfh cells were directly correlated with influenza-specific antibody avidity. Moreover, plasma testosterone levels were inversely correlated with antibody avidity index. The magnitude of microbial translocation [plasma lipopolysaccharide (LPS)] level was directly correlated with influenza-specific antibody avidity. Circulating 16S rDNA microbiome showed that enrichment of specific species within Proteobacteria was associated with influenza-specific antibody avidity. These results, including differences based on sex and correlations, were only observed in HIV-infected individuals but not in the healthy controls.
CONCLUSION: This study demonstrated sex differences in influenza-specific antibody avidity in ART-treated HIV disease, and provides valuable information on vaccination strategy in the ART-treated HIV-infected population.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30234599      PMCID: PMC6279558          DOI: 10.1097/QAD.0000000000002022

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  52 in total

1.  Isolates of the Enterobacter cloacae complex induce apoptosis of human intestinal epithelial cells.

Authors:  Sylwia Krzymińska; Ryszard Koczura; Joanna Mokracka; Tomasz Puton; Adam Kaznowski
Journal:  Microb Pathog       Date:  2010-05-06       Impact factor: 3.738

Review 2.  Germinal centers.

Authors:  Gabriel D Victora; Michel C Nussenzweig
Journal:  Annu Rev Immunol       Date:  2012-01-03       Impact factor: 28.527

Review 3.  The elusive identity of T follicular helper cells.

Authors:  Di Yu; Carola G Vinuesa
Journal:  Trends Immunol       Date:  2010-08-31       Impact factor: 16.687

4.  Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals.

Authors:  Joseph G Dauner; Yuanji Pan; Allan Hildesheim; Troy J Kemp; Carolina Porras; Ligia A Pinto
Journal:  Mol Cell Probes       Date:  2012-01-18       Impact factor: 2.365

5.  Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection.

Authors:  Xueling Wu; Zhenhai Zhang; Chaim A Schramm; M Gordon Joyce; Young Do Kwon; Tongqing Zhou; Zizhang Sheng; Baoshan Zhang; Sijy O'Dell; Krisha McKee; Ivelin S Georgiev; Gwo-Yu Chuang; Nancy S Longo; Rebecca M Lynch; Kevin O Saunders; Cinque Soto; Sanjay Srivatsan; Yongping Yang; Robert T Bailer; Mark K Louder; James C Mullikin; Mark Connors; Peter D Kwong; John R Mascola; Lawrence Shapiro
Journal:  Cell       Date:  2015-04-09       Impact factor: 41.582

Review 6.  The effects of hormones on sex differences in infection: from genes to behavior.

Authors:  S L Klein
Journal:  Neurosci Biobehav Rev       Date:  2000-08       Impact factor: 8.989

7.  Testosterone reduces macrophage expression in the mouse of toll-like receptor 4, a trigger for inflammation and innate immunity.

Authors:  Jennifer A Rettew; Yvette M Huet-Hudson; Ian Marriott
Journal:  Biol Reprod       Date:  2007-11-14       Impact factor: 4.285

Review 8.  Gender and autoimmunity.

Authors:  Gisele Zandman-Goddard; Elena Peeva; Yehuda Shoenfeld
Journal:  Autoimmun Rev       Date:  2006-11-13       Impact factor: 9.754

9.  High titer and avidity of nonneutralizing antibodies against influenza vaccine antigen are associated with severe influenza.

Authors:  Kelvin K W To; Anna J X Zhang; Ivan F N Hung; Ting Xu; Whitney C T Ip; Rebecca T Y Wong; Joseph C K Ng; Jasper F W Chan; Kwok-Hung Chan; Kwok-Yung Yuen
Journal:  Clin Vaccine Immunol       Date:  2012-05-09

10.  The impact of sex, gender and pregnancy on 2009 H1N1 disease.

Authors:  Sabra L Klein; Catherine Passaretti; Martha Anker; Peju Olukoya; Andrew Pekosz
Journal:  Biol Sex Differ       Date:  2010-11-04       Impact factor: 5.027

View more
  2 in total

1.  A link between IL-23 and anti-CD4 autoantibody production in antiretroviral-treated HIV-infected individuals.

Authors:  Zhenwu Luo; Min Li; Fuli Mi; Zhefeng Meng; Guoqiang Du; Lisa Martin; Hui Liu; Ping Jin; David Stroncek; Sonya L Heath; Wei Jiang
Journal:  J Virol       Date:  2021-03-17       Impact factor: 5.103

2.  Abnormal Shift in B Memory Cell Profile Is Associated With the Expansion of Circulating T Follicular Helper Cells via ICOS Signaling During Acute HIV-1 Infection.

Authors:  Xiaofan Lu; Xin Zhang; Allen Ka Loon Cheung; Christiane Moog; Huan Xia; Zhen Li; Rui Wang; Yunxia Ji; Wei Xia; Zhiying Liu; Lin Yuan; Xiuwen Wang; Hao Wu; Tong Zhang; Bin Su
Journal:  Front Immunol       Date:  2022-02-10       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.